Filing Details
- Accession Number:
- 0001209191-22-057195
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-15 20:32:51
- Reporting Period:
- 2022-11-11
- Accepted Time:
- 2022-11-15 20:32:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1835567 | Pear Therapeutics Inc. | PEAR | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1219014 | M Scott Rocklage | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1240357 | D John Diekman | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1589314 | 5Am Partners Iv, Llc | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1589315 | 5Am Ventures Iv, L.p. | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1593361 | 5Am Co-Investors Iv, L.p. | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1598549 | J. Andrew Schwab | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1753000 | 5Am Opportunities I, L.p. | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No | |
1790778 | 5Am Opportunities I (Gp), Llc | 501 2Nd Street, Suite 350 San Francisco CA 94107 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2022-11-11 | 28,205 | $3.19 | 12,909,354 | No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
Class A Common Stock | Disposition | 2022-11-11 | 1,175 | $3.19 | 537,891 | No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
Class A Common Stock | Disposition | 2022-11-14 | 11,643 | $2.79 | 12,897,711 | No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
Class A Common Stock | Disposition | 2022-11-14 | 485 | $2.79 | 537,406 | No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
Class A Common Stock | Disposition | 2022-11-15 | 61,222 | $2.52 | 12,836,489 | No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
Class A Common Stock | Disposition | 2022-11-15 | 2,551 | $2.52 | 534,855 | No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
No | 4 | S | Indirect | By 5AM Ventures IV, L.P. |
No | 4 | S | Indirect | By 5AM Co-Investors IV, L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Class A Common Stock | 3,372,769 | Indirect | By 5AM Opportunities I, L.P. |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
- The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.655 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein.